# Pembrolizumab and EDP1503 in Advanced Melanoma

> **NCT03595683** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 8 (actual)

## Conditions studied

- Melanoma (Skin)
- Melanoma

## Interventions

- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** EDP1503

## Key facts

- **NCT ID:** NCT03595683
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-02
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Drug supply no longer available.
- **Last updated:** 2025-12-08

## Collaborators

- Merck Sharp & Dohme LLC
- Evelo Biosciences, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595683, "Pembrolizumab and EDP1503 in Advanced Melanoma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03595683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*